Lv3
266 积分 2023-08-03 加入
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
2天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Visual predictive check of longitudinal models and dropout
2个月前
已完结
Examining P-gp efflux kinetics guided by the BDDCS – Rational selection of in vitro assay designs and mathematical models
3个月前
已完结
Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
4个月前
已完结
Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu corrected intercept method’ (FCIM)
6个月前
已完结
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
7个月前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview
7个月前
已完结
Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
7个月前
已完结
皖公网安备34019202002308
